Myelodysplastic myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a rare subset of myeloid malignancies characterized by overlapping clinical and pathological features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) that do not meet the specific diagnostic criteria for more defined entities such as Chronic Myelomonocytic Leukemia (CMML), atypical Chronic Myeloid Leukemia (aCML), or Juvenile Myelomonocytic Leukemia (JMML). Patients typically present with evidence of cytopenias (characteristic of MDS) alongside proliferative features such as leukocytosis, thrombocytosis, or splenomegaly (characteristic of MPN). Bone marrow analysis usually reveals dysplasia in one or more cell lines combined with hypercellularity. Genetic mutations are frequent, often involving genes like JAK2, TET2, ASXL1, and SRSF2, though no single mutation is pathognomonic for this unclassifiable category.
Distinguish from defined MDS/MPN entities by documenting the absence of specific diagnostic criteria for CMML, aCML, or JMML.
Example: Patient exhibits features of both myelodysplasia and myeloproliferation with persistent leukocytosis (WBC 18.2) and dysplastic neutrophils. Evaluation confirms BCR-ABL1 negative status and failure to meet the 10 percent monocyte threshold required for CMML-1. Bone marrow shows megakaryocytic atypia without the specific PDGFRA rearrangements. This supports C94.6 as an unclassifiable MDS/MPN. Billing focus: Molecular testing results integrated to justify diagnostic specificity. Risk adjustment: Condition categorized under HCC 11 (Myelodysplastic Syndromes and Myeloproliferative Neoplasms).
Billing Focus: Documentation of molecular markers (e.g., JAK2, BCR-ABL1 negative) and peripheral blood counts to exclude more specific codes.
Quantify marrow and peripheral blood blasts to ensure the condition has not progressed to acute myeloid leukemia.
Example: Bone marrow aspirate reveals 7 percent blasts with significant erythroid dysplasia and hypercellularity. Peripheral blood shows 3 percent blasts. The absence of 20 percent or higher blast count excludes AML, confirming the chronic MDS/MPN unclassifiable phase. Patient is currently transfusion dependent for Grade 3 anemia. Billing focus: Blast percentage documentation differentiates between chronic and acute myeloid codes. Risk adjustment: Transfusion dependence increases clinical complexity and resource utilization.
Billing Focus: Specific blast percentages (less than 20 percent) to maintain classification within C94.6.
Document presence or absence of splenomegaly and hepatomegaly as markers of myeloproliferative activity.
Example: Physical exam reveals palpable splenomegaly 4 cm below the left costal margin and hepatomegaly. Ultrasound confirms splenic length of 17 cm. The patient reports early satiety and left upper quadrant discomfort. These proliferative features co-exist with refractory macrocytic anemia and ring sideroblasts (12 percent). Billing focus: Physical exam findings support the MPN component of the diagnosis. Risk adjustment: Organomegaly indicates higher disease burden and severity of the myeloproliferative process.
Billing Focus: Physical exam findings of organomegaly to support the proliferative nature of the neoplasm.
Detail the specific lineages showing dysplasia, such as erythroid, myeloid, or megakaryocytic.
Example: Morphologic review of peripheral smear shows pseudo-Pelger-Huet anomaly in 30 percent of neutrophils and giant platelets. Bone marrow biopsy confirms multilineage dysplasia involving erythroid and megakaryocytic precursors. Patient lacks the isolated del(5q) abnormality. Billing focus: Multilineage dysplasia documentation supports the MDS component of C94.6. Risk adjustment: Multilineage involvement is associated with poorer prognosis than single-lineage dysplasia.
Billing Focus: Morphological descriptions of dysplasia across multiple cell lines.
Clearly state the lack of BCR-ABL1 translocation to differentiate from Chronic Myeloid Leukemia.
Example: Cytogenetic analysis via FISH is negative for t(9;22) BCR-ABL1 translocation. Despite leukocytosis and thrombocytosis, the negative FISH result precludes a diagnosis of CML. Clinical features overlap with MDS/MPN-U due to concurrent anemia and dysplastic changes. Billing focus: Mandatory exclusion of CML through cytogenetics for accurate use of C94.6. Risk adjustment: Validates the primary neoplastic diagnosis for hierarchical grouping.
Billing Focus: Inclusion of negative cytogenetic or molecular findings for BCR-ABL1.
Typically used for MDS/MPN-U follow-ups involving review of complex labs, managing cytopenias, and discussing treatment toxicity.
Appropriate for patients with disease progression, acute complications, or when coordinating multi-drug chemotherapy regimens.
Essential for the initial diagnosis and periodic restaging of MDS/MPN-U.
Required for morphologic confirmation of dysplasia and cellularity.
Used to identify blast percentage and specific lineage dysplasia.
Part of the workup to categorize the myeloproliferative aspect of the neoplasm.
Necessary to exclude CML, which is a requirement for the C94.6 diagnosis.
Used to monitor for dysplastic cells and circulating blasts.
Used for patients receiving hypomethylating agents like Azacitidine in a clinic setting.
Common supportive care for MDS/MPN patients with symptomatic cytopenias.
Used for routine monitoring in stable patients with minimal symptom burden.